SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 16.19 |
Enterprise Value ($M) | 8.61 |
Book Value ($M) | 6.49 |
Book Value / Share | 0.38 |
Price / Book | 2.49 |
NCAV ($M) | -6.90 |
NCAV / Share | -0.41 |
Price / NCAV | -2.35 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.87 |
Return on Assets (ROA) | -0.44 |
Return on Equity (ROE) | -1.08 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 2.62 |
Current Ratio | 2.62 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 24.27 |
Assets | 37.66 |
Liabilities | 31.17 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | -28.47 |
Net Income | -25.99 |
Earnings Per Share Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -20.86 |
Cash from Investing | 8.56 |
Cash from Financing | 0.08 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Alyeska Investment Group, L.P. | 9.99 | -0.53 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
13,364 | 54,749 | 24.41 | |
20,296 | 53,786 | 37.73 | |
41,019 | 92,814 | 44.19 | |
75,688 | 209,284 | 36.17 | |
38,608 | 102,099 | 37.81 | |
(click for more detail) |
Similar Companies | |
---|---|
TWST – Twist Bioscience Corporation | TXMD – TherapeuticsMD, Inc. |
TYRA – Tyra Biosciences, Inc. | UTHR – United Therapeutics Corporation |
VERV – Verve Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io